Introduction
============

Osteosarcoma, the most common primary bone malignancy, occurs most frequently in children and adolescents [@B1]. Although the development of combination treatment, including limb salvage surgery and neoadjuvant chemotherapy, has significantly increased the survival rates in patients with osteosarcoma from 20 to 75% [@B2]-[@B4], overall clinical outcomes remain unsatisfactory, especially for patients with metastasis or recurrent osteosarcoma. In recent years, accumulating evidence has validated numerous molecular alterations and tumor-related signaling pathways involved in the pathogenesis and progression of osteosarcoma [@B5], [@B6]. However, the highly complex molecular mechanism of osteosarcoma has not been elucidated. Thus, there is an urgent need to search for novel markers in order to develop new therapeutic strategies and predict clinical outcomes in osteosarcoma.

RPS9, a novel NPM1 interacting protein, is one of the first proteins that directly bind to the 18S rRNA [@B7]-[@B9]. RPS9 can be detected in the nucleoli and cytoplasm of mammalian cells [@B7] and it has been implicated in translation elongation, including mRNA unwinding and decoding accuracy. RPS9 plays an essential role in the early stages of ribosome biogenesis; knockdown of RPS9 results in the accumulation of the 45S and 30S pre-rRNAs, causing decreased global protein synthesis [@B10], [@B11]. Several studies have reported the role of RPS9 in tumorigenesis; however, the function and underlying mechanism of RPS9 in osteosarcoma remains unclear.

Mitogen-activated protein kinase (MAPK) is an insulin-mitogen activated protein (Ser/Thr) kinase [@B12]. Aberrant activation of MAPK can transmit extracellular signals to regulate processes such as cell growth, differentiation, migration, and apoptosis [@B13]. Loubeau *et al*. reported that NPM1 silencing reduced prostate cancer cell growth through the inhibition of MAPK signaling [@B14]. microRNA-7 has been known to constrain the activation of MAPK signaling pathway, thereby suppressing the proliferation and migration of NSCLC cells [@B15]. Similarly, extensive literatures have reported the significant role of MAPK signaling pathway in osteosarcoma [@B16], [@B17]. However, whether MAPK signaling pathway is involved in the RPS9-induced effects of osteosarcoma remains to be elucidated.

In this study, we investigated the expression of RPS9 in human osteosarcoma cell lines (MNNG/HOS, MG63, and U2OS) and in an osteoblast cell line (hFOB 1.19). RPS9 was found to be highly expressed in osteosarcoma cell lines. Similarly, high expression was found in osteosarcoma tissues compared to that in adjacent non-tumor tissues. The functions of RPS9 in osteosarcoma cells were further understood. Our results demonstrated that knockdown of RPS9 hindered osteosarcoma cell growth by inhibiting the G1 cell cycle. The underlying mechanism of RPS9 was also investigated. Reduced RPS9 levels down-regulated MAPK signaling in osteosarcoma cells. Notably, we found that RPS9 expression was positively correlated with the Enneking stage and the recurrence of osteosarcoma. To the best of our knowledge, this is the first report stating that over-expression of RPS9 might be a prerequisite for the development and progression of human osteosarcoma.

Materials and Methods
=====================

Cell lines and cell culture
---------------------------

Three osteosarcoma cell lines, namely MNNG/HOS, MG63 and U2OS, and one human osteoblast cell line hFOB 1.19 were obtained from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). They were cultured in either DMEM (MNNG/HOS and MG63) or RPMI-1640 (U2OS) containing 10% fetal bovine serum (Biowest, South America), 100 U/ml penicillin (Sigma-Aldrich, St Louis, MO, USA), and 100 mg/ml streptomycin (Sigma-Aldrich, St Louis, MO, USA). The cells were maintained at 37 °C in a humidified atmosphere containing 5% CO~2~. The hFOB 1.19 cell line was cultured according to established ATCC protocols.

Human osteosarcoma samples
--------------------------

From 2013 to 2014, a total of 50 patients with osteosarcoma were treated at the Shanghai Jiao Tong University Affiliated Sixth People\'s Hospital, who received primary surgical treatment and preoperative and postoperative neoadjuvant therapy. Each osteosarcoma sample, together with the corresponding non-tumor tissue sample, was obtained during surgery. The samples were immediately frozen in liquid nitrogen after resection and stored at -80 °C in a refrigerator. Ethics approval was obtained from the local hospital ethics committees, and written informed consent was obtained from each patient prior to sample collection.

RNA extraction and qRT-PCR analysis
-----------------------------------

Total RNA of human tissue samples and cultured cells was purified using Trizol reagent (Invitrogen, Carlsbad, CA, USA). cDNA was synthesized using a PrimeScript RT Reagent Kit (Takara, Shiga, Japan). qRT-PCR was performed using SYBR Green Premix Ex Taq (Takara, Shiga, Japan) on an ABI 7500 PCR system (Applied Biosystems). All reactions were performed in 10-μL reaction volumes in triplicate. The following primer sequences were used: RPS9: Forward: 5\'-GAAGCGGAGCCAACATGC-3\', Reverse: 5\'-ATACTCGCCGATCAGCTTCAG-3\'; β-actin: Forward: 5\'-TTGTTACAGGAAGTCCCTTGCC-3\', Reverse: 5\'-ATGCTATCACCTCCCCTGTGTG-3\'.

Protein extraction and western blotting analysis
------------------------------------------------

Lysates were extracted from cultured cells using T-PER Protein Extraction Reagent (Thermo Fisher Scientific) containing PhosSTOP (Roche, Basel, Switzerland) and Complete Mini (Roche, Basel, Switzerland). Equal amounts of proteins were electrophoresed and transferred onto Nitrocellulose membranes or PVDF membranes (Millipore, Billerica, MA, USA). After blocking in 5% non-fat milk, the membranes were incubated with the following primary antibodies: RPS9 (Proteintech, 1:250), SAPK/JNK (total) (Cell Signaling Technology, 1:1000), SAPK/JNK (Thr183/Tyr185) (Cell Signaling Technology, 1:1000), p38 (total) (BBI Life Sciences, 1:500), p38 (Thr180/Tyr182) (SAB Signalway Antibody, 1:500), or β-actin (Sigma-Aldrich, 1:20,000). The secondary antibody used in the study was anti-rabbit IgG (1:5000, Sigma-Aldrich). Visualization was performed using SuperSignal West Femto Maximum Sensitivity Substrate (Thermo Fisher Scientific).

siRNA transfection
------------------

Human RPS9 siRNA and siRNA nonspecific control were synthesized by Ribobio (Guangzhou, China) and were transfected into cells using Lipofectamine 2000 (Invitrogen) following the manufacturer\'s protocol. The sequence of siRNA targeting RPS9 was: GTCTCGACCAAGAGCTGAA. For proliferation and cell cycle assays, as well as for RNA extraction and western blotting, cells were used 48 h after transfection.

Cell proliferation assay and colony formation assay
---------------------------------------------------

### Cell proliferation assay

48 h after transfection, cells were seeded into a 96-well plate (3000 cells/well). A 10-μL aliquot of CCK-8 (Dojindo, Kumamoto, Japan) was added to the wells in triplicate, incubated for 2 h, and the absorbance at 450 nm was measured. Each measurement was performed in triplicate, and all experiments were repeated twice.

### Colony formation assay

48 h after siRNA transfection, MNNG/HOS, MG63, or U2OS cells (1 × 10^3^ cells/well) were cultured in 6-well plates for 10 days, followed by 100% methanol fixation for 30 min and 0.1% crystal violet staining for 30 min. The cell colonies were counted; all assays were independently performed in triplicate.

Cell cycle analysis
-------------------

Forty-eight hours after transfection, cells were collected and fixed with 70% ethanol. Subsequently, the cells were stained with 50 μg/mL propidium iodide (PI) (Kaiji, China) containing RNaseI (Kaiji, China), followed by analysis on a FACSCalibur flow cytometer (BD Biosciences, San Jose, CA). The results were analyzed using the ModFit software (BD Biosciences). Assays were performed three times independently.

Intracellular signaling array
-----------------------------

Forty-eight hours after transfection, the cells were harvested and lysed on ice with 0.1 ml of cell lysis buffer containing a cocktail of protease inhibitors for 5 min. The lysates were centrifuged at 10,000 *g* at 4 °C for 10 min. Intracellular signaling molecules were detected using a PathScan^®^ intracellular signaling array kit (Cell Signaling Technology, \#7744) according to the manufacturer\'s procedure. The fluorescent images of the slide were captured with Odyssey^®^ Infrared Imaging System (LI-COR) and intensities of the spots were quantified using Image Studio analysis software.

Immunohistochemistry (IHC) staining analysis
--------------------------------------------

A standard IHC staining procedure was followed. Briefly, paraffin-embedded sections (4-μm-thick) were dewaxed in xylene, followed by heating in a microwave at 60 °C for 20 min in EDTA buffer (pH 9.0) for antigen retrieval. For each slide, endogenous peroxidase activity was blocked by a 10-min incubation in 0.3% H~2~O~2~ followed by incubation at 37 °C with a 1:100 diluted primary antibody RPS9 (Proteintech, China). Slides were rinsed three times in PBS, incubated for 30 min with EnVision staining kit (DAKO, Denmark), followed by three additional washes in PBS, and color development over 3-10 min in a moist chamber at room temperature using 3,3′-diaminobenzidine (DAB). Thereafter, the slides were counterstained in hematoxylin and dehydrated using a graded series of ethyl alcohol (70%, 90%, and 100%). For sections used as negative controls, the primary antibody was substituted by PBS. IHC signal intensities were scored as follows: 0 (no staining), 1 (staining in \<1% cells), 2 (staining in 1%-10% cells), or 3 (staining in \>10% of cells). The samples scored as 0 and 1 were considered negative, while the samples scored as 2 and 3 were considered positive. Assessment of IHC staining was independently performed by two expert pathologists, and any discordance was resolved through discussion and consensus.

Statistical evaluation
----------------------

Data were compiled and analyzed using SPSS version 21.0 (SPSS Inc., Chicago, IL, USA). The differences between groups were compared using a two-tailed Student\'s *t*-test. Correlations between the IHC of RPS9 and the clinicopathological parameters were determined using the Chi-Square Test. A *P* \< 0.05 was considered significant.

Results
=======

RPS9 is overexpressed in osteosarcoma cell lines and human osteosarcoma tissue samples
--------------------------------------------------------------------------------------

To determine the role of RPS9 in osteosarcoma, we first detected the mRNA and protein expression levels of RPS9 in osteosarcoma cell lines and in the osteoblast cell line by qRT-PCR and western blotting analysis. Compared with the osteoblast cell line, both RPS9 mRNA and protein levels were overexpressed in osteosarcoma cell lines (Figure [1](#F1){ref-type="fig"}A, 1B and 1C). In order to confirm the role of RPS9, RPS9 expression levels were investigated in 20 paired sets of osteosarcoma and adjacent non-tumor tissues. As shown in Figure [1](#F1){ref-type="fig"}E and [1](#F1){ref-type="fig"}F, RPS9 expression was significantly upregulated in 55% (11/20) of osteosarcoma tissues compared to that in adjacent normal tissues. These results indicate that RPS9 may have an important role in osteosarcoma tumorigenesis, which warrants further investigation.

Knockdown of RPS9 inhibits osteosarcoma cell proliferation in vitro
-------------------------------------------------------------------

To explore the functional significance of RPS9 in osteosarcoma, RPS9-specific siRNA was used to knockdown RPS9 in osteosarcoma cells. RPS9 knockdown was validated using qRT-PCR and western blotting. RPS9 mRNA and protein expression were significantly reduced after transfection with RPS9-specific siRNA in MNNG/HOS, MG63, and U2OS cells (Figure [2](#F2){ref-type="fig"}A-[2](#F2){ref-type="fig"}F). Next, cell proliferation was detected using the Cell Counting Kit-8 (CCK-8) assay [@B18]. A 5-day growth curve analysis showed that knockdown of RPS9 significantly inhibited the growth of osteosarcoma cells (Figure [2](#F2){ref-type="fig"}G-[2](#F2){ref-type="fig"}I). The colony forming assay was carried out to determine the colony-forming capacity of osteosarcoma cells after knockdown of RPS9. It was found that both the number and the size of colonies were notably decreased in the RPS9 knockdown group compared to that in the control group (Figure [2](#F2){ref-type="fig"}J-2O). These results demonstrate that RPS9 plays an oncogenic role in osteosarcoma.

Knockdown of RPS9 inhibits osteosarcoma cell G1 cell cycle
----------------------------------------------------------

Changes in the cell cycle following RPS9 knockdown were analyzed by flow cytometry. Results of the cell cycle assay showed that RPS9-knockdown cells had a significantly higher percentage of cell population in the G1 phase of the cell cycle compared to the si-NC transfected cells (Figure [3](#F3){ref-type="fig"}A-[3](#F3){ref-type="fig"}I). However, no significant difference was found in populations in the S or G2/M phases of the cell cycle after RPS9 knockdown. In conclusion, the data showed that RPS9 knockdown attenuated osteosarcoma cell proliferation by inhibiting the G1 cell cycle transition.

Knockdown of RPS9 inhibits osteosarcoma cell proliferation through MAPK signaling pathway
-----------------------------------------------------------------------------------------

To determine the potential mechanism by which RPS9 affects the proliferation of osteosarcoma cells, intracellular signaling arrays were detected after RPS9 knockdown in MNNG/HOS cells and U2OS cells. A slight decrease in phosphorylation of some components, including p38-Thr180/Tyr182 and SAPK/JNK-Thr183/Tyr185, was detected in osteosarcoma cells (Figure [4](#F4){ref-type="fig"}A-[4](#F4){ref-type="fig"}D). Subsequently, we examined whether RPS9 could influence the MAPK signaling pathway in osteosarcoma cells using western blotting analysis. The results revealed that RPS9 knockdown inhibited the phosphorylation of SAPK/JNK and p38. Thus, these results support the possibility that RPS9 plays a crucial role in osteosarcoma cell growth by influencing the MAPK signaling pathway.

RPS9 expression is correlated with osteosarcoma Enneking stage and tumor recurrence
-----------------------------------------------------------------------------------

To further determine the clinicopathological significance of RPS9 in osteosarcoma, we performed an IHC analysis of RPS9 in 50 human osteosarcoma tissue samples and the corresponding non-tumor tissues. Representative IHC images of RPS9 expression in osteosarcoma tissues and non-tumor tissues are shown in Figure [5](#F5){ref-type="fig"}. Correlations between RPS9 expression level and clinicopathological characteristics of patients with osteosarcoma are summarized in Table [1](#T1){ref-type="table"}. RPS9 expression levels were found to be higher in osteosarcoma tissue samples than in the corresponding non-tumorous tissues (*P* = 0.012). The expression level of RPS9 was higher in patients at a clinically advanced Enneking stage than in patients at an early stage (*P* = 0.011). Further analysis found that the RPS9 level was positively correlated with recurrence (*P* = 0.024), indicating that RPS9 is involved in the recurrence of osteosarcoma. No correlation was found between RPS9 and any of the other factors, such as gender, age, tumor location, tumor necrosis rate, cortical destruction, and metastasis. Taken together, these results indicate that RPS9 is upregulated in osteosarcoma and potentially plays an important role in the progression of osteosarcoma.

Discussion
==========

Osteosarcoma is the most common type of malignant bone tumor characterized by high levels of genetic instability, with a peak incidence in the second and third decades of life [@B19]. The survival rate of patients has increased four-fold from the 1960s to the 1980s. However, the 5-year survival rates have remained unchanged during the last three decades, owing to the development of insensitivity to chemotherapy [@B20]. Uncovering the molecular mechanisms underlying the carcinogenesis and progression of osteosarcoma may help to identify effective therapies for treatment of the disease.

The ribosome is composed of two subunits consisting of a complex of ribosomal RNAs (rRNAs) and ribosomal proteins (RPs) [@B21]. Recently, ribosomal proteins have gained much attention for their role in extraribosomal processes, including DNA repair, apoptosis, proliferation, and metastasis [@B22], [@B23]. RPS3, a component of the 40S ribosomal submit, inhibits the invasion of fibrosarcoma cells by blocking the ERK pathway and MMP-9 secretion [@B24]. Proteomic profiling of an experimental tumor metastasis model determined 45 ribosomal proteins, of which several proteins were differentially expressed in metastatic M4A4 cells, including RPS10 and RPL39 [@B25]. Chen *et al*. reported that down-regulation of RPS6 inhibited the growth of non-small cell lung cancer by inducing G0-G1 cell cycle arrest and shortened the overall survival and relapse-free survival in p-rpS6-overexpressing patients [@B26].

In this study, we demonstrated that RPS9, a member of ribosomal proteins, was upregulated in osteosarcoma cell lines and osteosarcoma tissue samples in comparison with that in corresponding adjacent non-tumor tissues. Knockdown of RPS9 impaired osteosarcoma cell proliferation, as well as the colony-formation ability, and led to a G1 cell cycle arrest. These results indicated that RPS9 played a critical role in osteosarcoma cell growth by acting as an oncogene. Tian *et al*. reported that *RPS9* showed an aberrant promoter hypermethylation and played a critical role in colorectal tumorigenesis [@B27]. Another study showed that RPS9 silencing impaired 18S rRNA production and induced the activation of p53 in glioma cells, which subsequently resulted in the inhibition of cell proliferation [@B11]. However, Lemoine *et al*. reported that *RPS9* was down-regulated in pancreatic cancer tissues compared to in normal pancreas, thus suggesting its role as a tumor-suppressor gene in pancreatic cancer [@B28]. Through the analysis of putative prognostic markers (*CDK4*, *IGFBP2*, *MMP2*, and *RPS9*) in a set of 43 astrocytic gliomas, 41 glioblastomas, and 7 adjacent normal brain tissues, *RPS9* was found to be a significant favorable prognostic marker in gliomas [@B29]. Similarly, in the present study, we found that the expression of RPS9 was positively correlated with the recurrence and Enneking stage of osteosarcoma, as evidenced by the IHC staining results.

It has been reported that depletion of RPS9 can impair the production of 18S ribosomal RNA and thus reinitiate the differentiation process by inducing p53 activity [@B11]. Another study reported that RPS9 bound to NPM1 and that the expression of a subset of RPS9 deletion mutants resulted in altered nucleolar morphology, as evidenced by changes in the localization patterns of NPM1 [@B7]. In the present study, in order to further investigate the underlying mechanisms of RPS9, we used the intracellular signaling antibody array kit PathScan^®^ to identify the host signaling pathways that might be affected by knockdown of RPS9. The data revealed a slight decrease in phosphorylation of some components of MAPK pathway, including SAPK/JNK and p38, in RPS9-knockdown cells. Next, we detected changes in the MAPK pathway after RPS9 knockdown by western blotting. The results showed that knockdown of RPS9 inhibited the phosphorylation of SAPK/JNK and p38, indicating that RPS9 influences osteosarcoma progression partly through the MAPK signaling pathway. The possible underlying mechanism of RPS9 to regulate MAPK signaling pathway is as follows. It was reported that RPS9 was a novel NPM1 interacting protein [@B7]. Meanwhile, a previous literature reported that NPM1 silencing reduced prostate cancer cell growth through the inhibition of MAPK signaling [@B14]. Therefore, RPS9 may interact with NPM1 to regulate MAPK signaling pathway in osteosarcoma cells.

MAPK signaling pathway, which has been confirmed to be tightly associated with the proliferation of tumor cells [@B30], [@B31], including osteosarcoma cells [@B32], is an important intracellular signaling pathway. Cheng *et al*. reported that knockdown of S100A9 inhibited osteosarcoma cell proliferation through the inactivation of MAPK and NF-κB signaling pathways [@B33]. Zhang *et al*. reported that KiSS1 functioned as a tumor suppressor in osteosarcoma cells through inhibition of the MAPK pathway [@B34]. In addition, Li *et al*. showed that PLA2G16 enhanced metastatic osteosarcoma by activating the MAPK pathway [@B35].

In conclusion, we demonstrated, for the first time, that RPS9 was up-regulated in human osteosarcoma cell lines and clinical tissue samples. High expression of RPS9 was positively correlated with the Enneking stage and recurrence of osteosarcoma, which might be explained by the fact that RPS9 increased the proliferation of osteosarcoma cells. More importantly, we showed that RPS9 exerted oncogenic function through the MAPK signaling pathway in osteosarcoma cells. These data provide compelling evidence that RPS9 might serve as a potential therapeutic target for osteosarcoma.

Ethical approval
================

All procedures performed in studies involving human participants were in accordance with the ethical standards of Shanghai Jiao Tong University and with the principles of Declaration of Helsinki.
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![RPS9 is up-regulated in osteosarcoma tissues and cell lines. (A) (B) The mRNA and protein expression of RPS9 were measured by qRT-PCR and western blotting in osteosarcoma cell lines (MNNG/HOS, MG63, and U2OS) and in a human normal osteoblast cell line (hFOB 1.19). (C) The grey intensity was calculated in osteosarcoma cell lines and osteoblast cell line. β-actin was used as an internal control. (D) (E) The expression of RPS9 was detected in 20 pairs of osteosarcoma tissues and their adjacent non-tumor tissues. The expression of RPS9 was overexpressed in osteosarcoma tissues compared to that in non-tumor tissues. \* *P* \< 0.05.](jcav08p2720g001){#F1}

![Knockdown of RPS9 inhibits osteosarcoma cell growth in vitro. (A)-(F) Levels of mRNA and protein expression were validated after si-RPS9 transfection in MNNG/HOS cells, MG63 cells, and U2OS cells by qRT-PCR and western blotting, respectively. (G)-(I) Cell Counting Kit-8 (CCK-8) assays were performed after siRNA transfection. (J)-(O) Colony formation assays were performed for RPS9-silenced osteosarcoma cells and control cells. Data are representative of results from three independent experiments. \**P* \< 0.05.](jcav08p2720g002){#F2}

![Knockdown of RPS9 inhibits osteosarcoma cell G1 cell cycle transition. Representative images of the cell cycle assays in MNNG/HOS cells (A) (B), MG63 cells (D) (E), and U2OS cells (G) (H) after transfection with si-NC or si-RPS9. (C) (F) (I) Diagrams showing the results of cell cycle assay in MNNG/HOS cells, MG63 cells, and U2OS cells respectively. \**P* \< 0.05.](jcav08p2720g003){#F3}

![Knockdown of RPS9 inhibits MAPK signaling pathway in osteosarcoma cells. (A) (B) MNNG/HOS and U2OS cell extracts were prepared and analyzed using the intracellular signaling antibody array kit PathScan^®^(\#7744). Images were captured using Odyssey^®^ Infrared Imaging System (LI-COR). (C) (D) Diagrams show quantification of results in MNNG/HOS and U2OS cells respectively. (E) (F) (G) Western blotting analysis of MAPK signaling pathway, including SAPK/JNK and p38, in MNNG/HOS cells, MG63 cells, and U2OS cells respectively transfected with si-NC or si-RPS9.](jcav08p2720g004){#F4}

![Clinical significance of RPS9 in patients with osteosarcoma. (A) Representative IHC image of RPS9 in non-tumor tissues. (B) Representative IHC image of RPS9 in osteosarcoma tissues. Original magnification: 50×, 200×.](jcav08p2720g005){#F5}

###### 

Correlation analyses of RPS9 protein expression in relation to clinicopathologic variables of 50 patients with osteosarcoma

  Clinicopathologic parameters   Number of cases   RPS9 expression level   χ^2^   *p* value   
  ------------------------------ ----------------- ----------------------- ------ ----------- ---------
  Gender                                                                          0.002       0.963
  Male                           29                15                      14                 
  Female                         21                11                      10                 
  Age (years)                                                                     3.120       0.077
  \<18                           21                14                      7                  
  ≥18                            29                12                      17                 
  Location                                                                        3.356       0.187
  Femur                          25                16                      9                  
  Tibia                          17                6                       11                 
  Elsewhere                      8                 4                       4                  
  Tumor necrosis rate (%)                                                         0.037       0.848
  \<90                           39                20                      19                 
  ≥90                            11                6                       5                  
  Cortical destruction                                                            1.745       0.187
  Yes                            45                22                      23                 
  No                             5                 1                       4                  
  Recurrence                                                                      5.128       0.024\*
  Yes                            10                2                       8                  
  No                             40                24                      16                 
  Metastasis                                                                      0.087       0.768
  Yes                            24                13                      11                 
  No                             26                13                      13                 
  Ennecking stage                                                                 6.462       0.011\*
  Ⅱ                              39                24                      15                 
  Ⅲ                              11                2                       9                  

\**P*\<0.05
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